Myriad Genetics, Inc. Class Action Lawsuit - MYGN

The filed complaint alleges that Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. Specifically, market analysts reported that a document from UnitedHealth stated that the coverage is ending as tests for behavioral health, which includes GeneSight, are "unproven" and "not medically necessary." Following this news, Myriad's stock price fell over 18% on November 1, 2024.

In order to be eligible to join the MYGN class action lawsuit, you must have incurred a loss on shares of Myriad Genetics, Inc. purchased during the class period listed above.